Crispr Therapeutics Ag (CRSP)

$52.53 +1.42 (2.78%)
Market Cap 5.01B
Revenue (ttm) 37.31M
Net Income (ttm) -366.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -981.64%
Debt to Equity Ratio 0.00
Volume 4,266,800
Avg Vol 2,600,324
Day's Range N/A - N/A
Shares Out 95.30M
Stochastic %K 30%
Beta 1.89
Analysts Strong Sell
Price Target $82.22

Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 41 561 32 77
Address:
Baarerstrasse 14, Zug, Switzerland
WallStreetBuyDip
WallStreetBuyDip Nov. 17 at 6:13 AM
$CRSP trading at $53 with 72% above-average volume, while $MRNA at $25 with volume 16% below average. CRSP showing more strength in the Genomics sector compared to MRNA. Will we see a shift in momentum soon with these two?
0 · Reply
EBE_day
EBE_day Nov. 17 at 1:32 AM
$CRSP cholesterol study even though early on is massive. This is a big deal.
0 · Reply
ChristopherBrecher
ChristopherBrecher Nov. 17 at 12:58 AM
$CRSP I like it near support.
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 16 at 10:45 PM
Hedge Alert Live - Protect Your Portfolio Contract: $CRSP $52.50 Put · NOV 21, 2025 Exp Entry Price: $2.07 - $3.80 Exit Price Target: $4.70 Profit Margin: +127% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
imatisse
imatisse Nov. 16 at 9:14 PM
$LCTX “We know the problem, we’re working on it, here’s the timeline.” $IPSC $CRSP $VRTX
0 · Reply
JDR1983
JDR1983 Nov. 16 at 4:48 PM
$CRSP This is a $200+ stock.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 16 at 1:16 PM
Enter: $CRSP Calls Strike Price: $53 Expiry Date: DEC 05 2025 Buy in Price: $2.15 - $2.70 Sell Price: $3.98 Profit : +85% (Turn every $1 into $1.85) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Maisierocks
Maisierocks Nov. 16 at 8:07 AM
$CRSP bounced off 200 day moving average
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 16 at 1:47 AM
💎 LiquidTheta® Live Actionable Trade Asset: $CRSP Contracts: $CRSP January 15, 2027 $55 Calls Scale in: $13.61- $16.64 Scale out: $52.94-$90.75 Profit Potential : 91% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 15 at 10:48 PM
Hedge Alert Live - Protect Your Portfolio Contract: $CRSP $52.50 Put · NOV 21, 2025 Exp Entry Price: $2.07 - $3.80 Exit Price Target: $4.70 Profit Margin: +127% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Latest News on CRSP
CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy

Nov 13, 2025, 3:43 PM EST - 3 days ago

CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 6 days ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study

Nov 8, 2025, 10:03 AM EST - 8 days ago

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

Nov 8, 2025, 9:56 AM EST - 8 days ago

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

Oct 10, 2025, 8:00 AM EDT - 5 weeks ago

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Oct 1, 2025, 8:00 AM EDT - 6 weeks ago

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track

Sep 17, 2025, 4:09 PM EDT - 2 months ago

Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Sep 9, 2025, 4:00 PM EDT - 2 months ago

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

Sep 9, 2025, 2:22 PM EDT - 2 months ago

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

INCY XBI XLV

CRISPR Therapeutics AG (CRSP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 11:38 AM EDT - 2 months ago

CRISPR Therapeutics AG (CRSP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

CRISPR Therapeutics AG (CRSP) Presents at H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 9, 2025, 6:53 AM EDT - 2 months ago

CRISPR Therapeutics AG (CRSP) Presents at H.C. Wainwright 27th Annual Global Investment Conference Transcript

Crispr Therapeutics: A Winning Lottery Ticket Doesn't Replace Grand Strategy

Sep 2, 2025, 8:55 AM EDT - 2 months ago

Crispr Therapeutics: A Winning Lottery Ticket Doesn't Replace Grand Strategy

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Sep 2, 2025, 8:00 AM EDT - 2 months ago

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Crispr Therapeutics: A Speculative Buy With Promising Potential Ahead

Aug 27, 2025, 6:21 AM EDT - 2 months ago

Crispr Therapeutics: A Speculative Buy With Promising Potential Ahead

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

Aug 14, 2025, 1:02 PM EDT - 3 months ago

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

AMD ARKF ARKG ARKK ARKQ ARKW ARKX

Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025

Aug 14, 2025, 7:27 AM EDT - 3 months ago

Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 4:15 PM EDT - 3 months ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big

Jul 23, 2025, 11:03 AM EDT - 4 months ago

Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big

The Big 3: ASML, GOOGL, CRSP

Jul 15, 2025, 12:01 PM EDT - 4 months ago

The Big 3: ASML, GOOGL, CRSP

ASML GOOG GOOGL

Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade)

Jul 14, 2025, 8:00 AM EDT - 4 months ago

Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade)

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

Jun 26, 2025, 7:00 AM EDT - 5 months ago

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

The Big 3: CRSP, OKLO, GME

Jun 23, 2025, 12:01 PM EDT - 5 months ago

The Big 3: CRSP, OKLO, GME

OKLO GME

Crispr Therapeutics: Betting On A One-Shot Future

Jun 13, 2025, 6:27 PM EDT - 5 months ago

Crispr Therapeutics: Betting On A One-Shot Future

CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Jun 9, 2025, 5:50 PM EDT - 5 months ago

CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)

Jun 3, 2025, 4:07 PM EDT - 5 months ago

CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)

Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines

May 9, 2025, 7:14 AM EDT - 6 months ago

Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines

CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)

May 8, 2025, 8:36 AM EDT - 6 months ago

CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)

Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course

May 7, 2025, 4:03 PM EDT - 6 months ago

Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

May 7, 2025, 2:17 PM EDT - 6 months ago

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results

May 7, 2025, 8:39 AM EDT - 6 months ago

These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

May 6, 2025, 4:01 PM EDT - 6 months ago

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

May 5, 2025, 4:44 AM EDT - 6 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

NTLA

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)

Apr 8, 2025, 3:29 PM EDT - 7 months ago

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 8 months ago

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics Announces Transition of Chief Operating Officer

Mar 26, 2025, 4:01 PM EDT - 8 months ago

CRISPR Therapeutics Announces Transition of Chief Operating Officer

CRISPR Therapeutics Set To Reach Previous Heights

Mar 25, 2025, 11:03 AM EDT - 8 months ago

CRISPR Therapeutics Set To Reach Previous Heights

CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)

Mar 3, 2025, 3:28 PM EST - 9 months ago

CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 9 months ago

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future

Feb 13, 2025, 11:06 AM EST - 9 months ago

Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 11, 2025, 4:01 PM EST - 9 months ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)

Feb 5, 2025, 4:16 PM EST - 10 months ago

CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)

Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)

Feb 5, 2025, 3:48 PM EST - 10 months ago

Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers

Jan 15, 2025, 7:20 PM EST - 10 months ago

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers

CRISPR Therapeutics AG (CRSP) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Jan 14, 2025, 7:39 PM EST - 10 months ago

CRISPR Therapeutics AG (CRSP) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 8:30 AM EST - 11 months ago

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025

Dec 29, 2024, 12:56 PM EST - 11 months ago

Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

Dec 9, 2024, 12:00 PM EST - 1 year ago

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)

Nov 20, 2024, 9:28 PM EST - 1 year ago

CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)

CRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)

Nov 15, 2024, 11:37 AM EST - 1 year ago

CRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 14, 2024, 8:30 AM EST - 1 year ago

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

WallStreetBuyDip
WallStreetBuyDip Nov. 17 at 6:13 AM
$CRSP trading at $53 with 72% above-average volume, while $MRNA at $25 with volume 16% below average. CRSP showing more strength in the Genomics sector compared to MRNA. Will we see a shift in momentum soon with these two?
0 · Reply
EBE_day
EBE_day Nov. 17 at 1:32 AM
$CRSP cholesterol study even though early on is massive. This is a big deal.
0 · Reply
ChristopherBrecher
ChristopherBrecher Nov. 17 at 12:58 AM
$CRSP I like it near support.
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 16 at 10:45 PM
Hedge Alert Live - Protect Your Portfolio Contract: $CRSP $52.50 Put · NOV 21, 2025 Exp Entry Price: $2.07 - $3.80 Exit Price Target: $4.70 Profit Margin: +127% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
imatisse
imatisse Nov. 16 at 9:14 PM
$LCTX “We know the problem, we’re working on it, here’s the timeline.” $IPSC $CRSP $VRTX
0 · Reply
JDR1983
JDR1983 Nov. 16 at 4:48 PM
$CRSP This is a $200+ stock.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 16 at 1:16 PM
Enter: $CRSP Calls Strike Price: $53 Expiry Date: DEC 05 2025 Buy in Price: $2.15 - $2.70 Sell Price: $3.98 Profit : +85% (Turn every $1 into $1.85) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Maisierocks
Maisierocks Nov. 16 at 8:07 AM
$CRSP bounced off 200 day moving average
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 16 at 1:47 AM
💎 LiquidTheta® Live Actionable Trade Asset: $CRSP Contracts: $CRSP January 15, 2027 $55 Calls Scale in: $13.61- $16.64 Scale out: $52.94-$90.75 Profit Potential : 91% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 15 at 10:48 PM
Hedge Alert Live - Protect Your Portfolio Contract: $CRSP $52.50 Put · NOV 21, 2025 Exp Entry Price: $2.07 - $3.80 Exit Price Target: $4.70 Profit Margin: +127% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 15 at 8:58 AM
Enter: $CRSP Calls Strike Price: $53 Expiry Date: DEC 05 2025 Buy in Price: $2.15 - $2.70 Sell Price: $3.98 Profit : +85% (Turn every $1 into $1.85) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
QuantInsider
QuantInsider Nov. 15 at 3:34 AM
$CRSP showing some serious momentum today Big 584-contract sweep in those 11/21 $57 calls at $0.85 That's a hefty $49.6k premium and it's all about new bullish exposure Feels like they're betting on a move Today's +2.78% pop is a nice contrast to that recent 2.01% slide over the last five days Could be a setup for more upside into next week Keep an eye on it Looking for early-week follow-through to confirm any trend shift Tactical longs might be the play here
0 · Reply
IBott
IBott Nov. 15 at 3:28 AM
$CRSP Over 40,000 more shares bought today by ARK. Cathie can’t pass up a bargain!
1 · Reply
FlippinLinknz
FlippinLinknz Nov. 15 at 2:37 AM
$CRSP May jump back in.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 15 at 1:27 AM
💎 LiquidTheta® Live Actionable Trade Asset: $CRSP Contracts: $CRSP January 15, 2027 $52 Calls Scale in: $12.82- $15.66 Scale out: $49.84-$85.44 Profit Potential : 111% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
muskegbaymomentum
muskegbaymomentum Nov. 14 at 11:57 PM
$CRSP so undervalued for the upside. Been bullish on the crsp for many years. I just don't get the bear case on this stonk. Always thought it was a slam dunk. Break through situations in multiple areas. High upside still i guess i can say. ( working for medical device companies for many years has probably made me very pro CRSP. ) I want suffering people to have a better quality of life.
0 · Reply
red619
red619 Nov. 14 at 11:31 PM
$CRSP i just need the 20k buy in
0 · Reply
NwordFslur
NwordFslur Nov. 14 at 10:04 PM
$CRSP This should be 80 at least
0 · Reply
svertical1
svertical1 Nov. 14 at 8:53 PM
$CRSP Would be surprised to NOT see a buyout of CRSP within the next year. Imagine if you could buy a house while also utilizing the owners bank account for the purchase. My guess is $12-20B. VRTX most likely as they’d get 100% of CASGEVY revenue and CASGEVY also received Voucher.
0 · Reply
Thelonius_Stonk
Thelonius_Stonk Nov. 14 at 8:00 PM
$CRSP dang
3 · Reply
Dr_Anton_Phibes
Dr_Anton_Phibes Nov. 14 at 7:58 PM
$CRSP not to mass post but this is a pretty good comment: "“Ninety-per cent of the time a cheap stock or bond is beaten up for a good reason but sometimes we find excellent companies that the market has cast aside for really bad reasons,” Mr Cutler said."
0 · Reply
Dr_Anton_Phibes
Dr_Anton_Phibes Nov. 14 at 7:55 PM
$CRSP well... LOL! I stand corrected, I'm glad these guys put their money in CRSP! "Orbis Investment’s Bermudian-based multi-asset investment team has been named fund manager of the year by British magazine Investment Week. This is the third consecutive year that Orbis director and portfolio manager Alec Cutler and his team have won the award" https://www.royalgazette.com/reinsurance/business/article/20250708/bermuda-orbis-team-tops-global-investment-fund-managers/
0 · Reply